But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
An FDA advisory committee refuses to overlook the potential dangers of roxadustat, Fibrogen's novel anaemia pill, leaving partner Astrazeneca with a difficult…
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?